December 29, 2020
1 min watch
VIDEO: ‘Exciting’ therapies in the pipeline for IBD
Afzali reports acting as a consultant for AbbVie, Celgene, Janssen, Takeda and UCB; and receiving speaker fees from AbbVie, Janssen, Pfizer, Takeda and UCB.
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com.
In this exclusive video, Anita Afzali, MD, director of the inflammatory bowel disease center at The Ohio State University, discusses the impact of emerging therapies in IBD.
In addition to filling in some of the unmet needs in IBD care, Afzali said new therapies could help physicians provide a more personalized approach for their patients.